Opendata, web and dolomites

ClearRing SIGNED

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ClearRing project word cloud

Explore the words cloud of the ClearRing project. It provides you a very rough idea of what is the project "ClearRing" about.

authorisation    company    therapy    hyperplasia    patient    life    clearring    preservers    significantly    validation    efficacy    trial    men    carry    shaped    patients    introduce    procedure    quality    90    resume    comparatively    normal    health    operation    validate    treatment    clinical    urological    reimbursement    benign    function    causing    fast    encrustation    sexual    seek    risk    first    watchful    million    surgery    affordable    invasive    hospitals    undesirable    symptoms    costly    gradually    implantable    safety    proarc    medical    centres    instead    enlarges    bothersome    mark    ce    migration    urinary    puts    age    lifestyles    chance    drugs    70    implant    waiting    diseases    revolutionary    potentially    200    complications    bph    alternative       worsening    twice    prostatic    blocks    60s    reduces    prostate    inside    worldwide    enlargement    safe    position    whereas    urethra    obtain    presses    severity    minimally    rapid    unmet    tolerable    efficient    standard    randomized    solution   

Project "ClearRing" data sheet

The following table provides information about the project.

Coordinator
PROARC MEDICAL LTD 

Organization address
address: KIDMA 23
city: PARDES HANA
postcode: 3707923
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙776˙750 €
 EC max contribution 1˙943˙725 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROARC MEDICAL LTD IL (PARDES HANA) coordinator 1˙943˙725.00

Map

 Project objective

Benign Prostatic Hyperplasia (BPH), or prostate enlargement, is one of the most common urological diseases among men. As the prostate enlarges with the age, it presses on and blocks the urethra, causing bothersome urinary symptoms. Over 70% of men in their 60s have symptoms of BPH 1, and 80-90% of men over 80 year old. BPH affects around 200 million men worldwide. The current methods present a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more tolerable, and comparatively safe alternative to drugs and invasive surgery, which carry greater risk of undesirable side effects and complications. ClearRing is a revolutionary treatment of BPH symptoms, based on a pre-shaped implant and a dedicated delivery system. The ClearRing solution is the only minimally invasive system for BPH which is implantable inside the prostate with 0% chance of migration or encrustation. It puts ProArc in a unique position as a first company providing significantly improved health conditions and quality of life. Its rapid procedure enables hospitals to get patients in and out more quickly, creating a better patient experience as well as a more efficient management of medical resources. The minimally invasive procedure reduces the range and severity of side effects allowing patients to resume their normal lifestyles potentially twice as fast as the current standard operation procedure. Furthermore, it preservers sexual function. Overall objective of ProArc is to introduce a BPH treatment which is effective, affordable and with no side-effects, therefore men seek for the treatment instead of watchful waiting for the worsening. Whereas, the key objective of the project is to validate the ClearRing safety and efficacy for BPH treatment through a randomized clinical trial at 3 medical centres. This large scale clinical validation will enable ProArc to obtain the CE mark, and gradually apply for the reimbursement authorisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLEARRING" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CLEARRING" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More